Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lantus
Glargine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Standard insulin drip therapy | NO_INTERVENTION | Standard insulin drip therapy |
| Insulin drip and glargine | ACTIVE_COMPARATOR | Insulin drip and glargine 0.25 units per kg body weight |
| Name | Type | Description |
|---|---|---|
| Glargine | DRUG | Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy |
Inclusion Criteria: * Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar non-ketotic states, hyperglycemia with severe illness, pre- and postoperative states, nothing by mouth (NPO), as well as gastric (tube feeding) and parenteral nutrition requiring insulin drip. * Patients with type 1 an...
Glargine is being studied for the treatment of diabetes. It is a long-acting insulin therapy developed by Sanofi. The clinical program has focused on evaluating its use in diabetes management, including a completed Phase 1 trial that examined adding subcutaneous long-acting Glargine to insulin drip therapy compared with standard insulin drip therapy.
Glargine acts as an agonist at the insulin receptor (INSR). By binding to and activating INSR, it mimics the action of endogenous insulin, supporting glucose uptake and regulation. This mechanism underlies its development as a long-acting insulin therapy for diabetes.
Glargine is developed by Sanofi, which trades under the ticker SNY. Sanofi is the company responsible for the clinical development of this long-acting insulin candidate for diabetes.
Glargine is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 1 program includes one completed trial evaluating its use in diabetes.
Glargine has been evaluated in one completed Phase 1 trial, NCT01153100, titled "Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy." The trial enrolled 60 participants with diabetes in the United States and used an active-controlled, randomized design.